Recurrent Malignant Testicular Germ Cell Tumor Completed Phase 2 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0028803 (Recurrent Malignant Testicular Germ Cell Tumor)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00467051Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell TumorsTreatment